The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Cota Healthcare; Eisai; Goldilocks; Lilly; Regeneron; UpToDate
Research Funding - Plexxikon; Regeneron
 
Nathan R. Foster
No Relationships to Disclose
 
Yungpo Bernard Su
No Relationships to Disclose
 
Ardaman Shergill
Consulting or Advisory Role - Triptych Health Partners
Research Funding - Daiichi Sankyo/Lilly (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst); TP Therapeutics (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Bhavana Konda
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Xencor (Inst)
 
Ronald A Ghossein
No Relationships to Disclose
 
Ian Ganly
No Relationships to Disclose
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; JOHNSON AND JOHNSON COM; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech